Testing gene changes and DNA damage in HER2-low breast cancer
Part of Cancer, Skin clinical trials.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between ages 18 and 70
- You have confirmed HER2-low breast cancer (HER2 IHC 1+ or IHC 2+ but ISH negative)
- You are able to do normal daily activities most of the time (ECOG 0–1)
- Your breast cancer has not been treated yet, and you are planned for curative surgery (operable primary cancer)
- Your cancer has been checked for DNA damage/HRD, and you have the tumor and blood samples available for testing
- The cancer has not spread to distant organs (no distant metastasis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a new drug that targets breast cancer cells with low levels of the HER2 protein. It may offer a new treatment option for patients whose cancer has spread and not responded well to previous therapies.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.